Atomwise
AI drug discovery platform that uses deep learning to screen and identify novel small-molecule drug candidates across large chemical spaces.
About
Atomwise (now transitioning programs under the Numerion Labs name) applies AI-driven molecular screening to small-molecule drug discovery. Its core technology explores vast chemical spaces to surface drug-like molecules with potential against difficult targets, with a current focus on immune and inflammatory diseases. The platform has supported research partnerships with major pharmaceutical companies, including a multi-target collaboration with Sanofi. Atomwise works with biopharma partners and academic institutions rather than selling a self-serve product; all engagements are research partnerships with milestone-based commercial arrangements.